3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
35
Motor Activity
25
Breast Neoplasms
5
Urinary Bladder Neoplasms
4
Colorectal Neoplasms
4
Neoplasms
3
Fatigue
3
Carcinoma, Renal Cell
3
Ovarian Neoplasms
2
Obesity
2
Kidney Neoplasms
2
Urologic Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Smoking
1
Sleep Initiation and Maintenance Disorders
1
Risk Reduction Behavior
1
Prostatectomy
1
Postoperative Complications
1
Peripheral Nervous System Diseases
1
Patient Preference
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Metabolic Syndrome
1
Mesothelioma, Malignant
1
Malnutrition
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Insulin Resistance
1
Hypoxia
1
Interventions
sagopilone
1
pembrolizumab
1
glutamic acid diethyl ester
1
enfortumab vedotin
1
allantoicase
1
Prednisolone
1
Glutamine
1
Glutamic Acid
1
Exercise
1
Dietary Supplements
1
BID protein, human
1
Acupuncture Therapy
1
Acetylcarnitine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Peripheral Nervous System Diseases
×
Exercise
×
Genitourinary
×
Clear all
NCT07548476
2026-05-04
ACE
Dana-Farber Cancer Institute
Phase NA
Not yet recruiting
50 enrolled